The ACORN Study: Nephrotoxoicity in Antibiotics

Piperacillin/tazobactam and vancomycin have been reported in numerous clinical trials to be associated with acute kidney injury. Comparatively, cefepime with vancomycin may increase neurotoxic effects. Join host, Geoff Wall, as he evaluates a new randomized controlled trial evaluating the safety of these medications. The GameChangerVancomycin, even at appropriate doses, can cause nephrotoxicity. Piperacillin/tazobactam does not seem to increase the risk of adverse kidney outcomes. However, cefepime is associated with an increased risk of neurologic toxicity. HostGeoff Wall, PharmD, BCPS, FCCP, BCGPProfessor of Pharmacy Practice, Drake UniversityInternal Medicine/Critical Care, UnityPoint Health ReferenceTong SYC, Venkatesh B, McCreary EK. Acute Kidney Injury With Empirical Antibiotics for Sepsis. JAMA. 2023;330(16):1531–1533. doi:10.1001/jama.2023.18591https://jamanetwork.com/journals/jama/fullarticle/2810593 Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE Information Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the risk of nephrotoxicity with piperacillin/tazobactam2. Discuss the factors that exacerbate neurologic adverse effects with cefepime0.05 CEU/0.5 HrUAN: 0107-0000-23-353-H01-P Initial release date: 11/13/2023Expiration date: 11/13/2024Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram